Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|September 5, 2019
Quiz: What is the best state to live in if you have rheumatoid arthritis?
In this installment of our monthly rheumatoid arthritis quiz, we focus comorbidities associated with rheumatoid arthritis, adverse drug reactions and the best place to get care in the country. Learn more in this quiz.
Advertisement
In this installment of our monthly rheumatoid arthritis quiz, we focus comorbidities associated with rheumatoid arthritis, adverse drug reactions and the best place to get care in the country. Learn more in this quiz.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement